Lidia Timofeenko Petersen
Psychiatric/Mental Health · Las Vegas, NVNPI 1245857952
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,913 of the $6,037 with a category attached, or 81.4%. It is spread thinly across 10 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,857, more than ten times the $166 reported in 2022. Among psychiatric/mental health clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $27.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$893
- Teva Pharmaceuticals USA, Inc.$856
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$790
- Alkermes, Inc.$759
- Neurocrine Biosciences, Inc.$699
- plus $736 from 4 others
What the payments were for
- Consulting fees$81213%
- Food & beverage$4,91381%
- Education$3125%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $1,303 |
| Johnson & Johnson | 29 | $893 |
| Teva Pharmaceuticals USA, Inc. | 40 | $856 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $790 |
| Alkermes, Inc. | 33 | $759 |
| Neurocrine Biosciences, Inc. | 29 | $699 |
| E.r. Squibb & Sons, L.L.C. | 15 | $317 |
| AbbVie | 13 | $246 |
| Indivior Inc. | 9 | $151 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$937
- ARISTADA$500
- CAPLYTA$286
- INVEGA SUSTENNA$234
- INGREZZA$175
- ABILIFY ASIMTUFII$125
- ARISTADA INITIO$125
How this compares
$6,037 in reported general payments places this provider in the 90th percentile of 362 psychiatric/mental health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 27 | $66,310 |
| AristadaAripiprazole Lauroxil | 15 | $53,711 |
| CaplytaLumateperone Tosylate | 18 | $31,297 |
| Clozapine | 39 | $4,462 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $3,943 |
| Divalproex Sodium ErDivalproex Sodium | 38 | $2,786 |
| Haloperidol | 35 | $2,211 |
| Divalproex Sodium | 82 | $2,011 |
| Aripiprazole | 11 | $1,686 |
| Hydroxyzine Hcl | 57 | $1,069 |
| Olanzapine | 66 | $1,050 |
| Fluoxetine Hcl | 35 | $891 |
| Haloperidol Decanoate | 12 | $782 |
| Trazodone Hcl | 81 | $706 |
| Quetiapine Fumarate | 52 | $619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $893 | $66,31027 claims |
| Alkermes, Inc.Aristada | $759 | $53,71115 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $790 | $31,29718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 362 psychiatric/mental health providers in Nevada.
Other psychiatric/mental health in Las Vegas
- Michelle GiddingsLas Vegas$131K
- Patrick ApiladoLas Vegas$19K
- Joshua HamiltonLas Vegas$17K
- Sydney EganLas Vegas$14K
- Ma Victoria EscardaLas Vegas$12K
- Carminia SalvacionLas Vegas$12K
- Valentina AkohLas Vegas$12K
- Angela WilsonLas Vegas$11K
- Michael MathisenLas Vegas$10K
- Edina BorosLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.